Next Article in Journal
Self-reported cannabis products and other illicit drugs consumption in older school-age children in Northern Lithuania: A comparison between 2006 and 2012
Previous Article in Journal
Predictive value of early near-infrared spectroscopy monitoring of patients with traumatic brain injury
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 52
Issue 2
10.1016/j.medici.2016.02.002
medicina-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences (LUHS), and Vilnius University.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Multidrug-resistant tuberculosis in Lithuania – Still a long way ahead

by
Greta Musteikienė
1,*,
Skaidrius Miliauskas
1,
Raimundas Sakalauskas
1,
Astra Vitkauskienė
2 and
Marius Žemaitis
1
1
Department of Pulmonology and Immunology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
2
Department of Laboratory Medicine, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
*
Author to whom correspondence should be addressed.
Medicina 2016, 52(2), 69-78; https://doi.org/10.1016/j.medici.2016.02.002
Submission received: 30 July 2015 / Revised: 1 February 2016 / Accepted: 13 February 2016 / Published: 3 March 2016
Versions Notes

Abstract

Despite the recent advances in the diagnosis of tuberculosis, treatment of the disease, for the most part, remains the same as it was half a century ago. In recent years only two new antituberculosis drugs have been approved by the European Medicines Agency and Food and Drug Administration. Though the prevalence of this disease is slowly decreasing all over Europe, new challenges appear. One of them is multidrug-resistant tuberculosis (MDR-TB). This problem is especially prominent in Lithuania, which is one of the 27 high MDR-TB burden countries in the world and falls behind neighboring countries in terms of the prevalence of the disease. The objective of this paper was to review the situation of tuberculosis and MDR-TB in Lithuania, and current available methods of treatment, control and diagnosis of this disease.
Keywords: Tuberculosis; Multidrug-resistant tuberculosis; Extensively drug-resistant tuberculosis; Anti-tuberculosis drugs Tuberculosis; Multidrug-resistant tuberculosis; Extensively drug-resistant tuberculosis; Anti-tuberculosis drugs

Share and Cite

MDPI and ACS Style

Musteikienė, G.; Miliauskas, S.; Sakalauskas, R.; Vitkauskienė, A.; Žemaitis, M. Multidrug-resistant tuberculosis in Lithuania – Still a long way ahead. Medicina 2016, 52, 69-78. https://doi.org/10.1016/j.medici.2016.02.002

AMA Style

Musteikienė G, Miliauskas S, Sakalauskas R, Vitkauskienė A, Žemaitis M. Multidrug-resistant tuberculosis in Lithuania – Still a long way ahead. Medicina. 2016; 52(2):69-78. https://doi.org/10.1016/j.medici.2016.02.002

Chicago/Turabian Style

Musteikienė, Greta, Skaidrius Miliauskas, Raimundas Sakalauskas, Astra Vitkauskienė, and Marius Žemaitis. 2016. "Multidrug-resistant tuberculosis in Lithuania – Still a long way ahead" Medicina 52, no. 2: 69-78. https://doi.org/10.1016/j.medici.2016.02.002

APA Style

Musteikienė, G., Miliauskas, S., Sakalauskas, R., Vitkauskienė, A., & Žemaitis, M. (2016). Multidrug-resistant tuberculosis in Lithuania – Still a long way ahead. Medicina, 52(2), 69-78. https://doi.org/10.1016/j.medici.2016.02.002

Article Metrics

Back to TopTop